Loading...
XNASATAI
Market cap201mUSD
Dec 23, Last price  
1.20USD
1D
0.84%
1Q
1.69%
IPO
-93.97%
Name

ATAI Life Sciences NV

Chart & Performance

D1W1MN
XNAS:ATAI chart
P/E
P/S
641.28
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
314k
+34.76%
0020,376,000233,000314,000
Net income
-40m
L-71.56%
-17,476,000-102,118,000-132,612,000-141,411,000-40,224,000
CFO
-84m
L-19.48%
-7,846,000-20,766,000-63,246,000-104,467,000-84,118,000
Dividend
Aug 27, 20186 USD/sh
Earnings
Mar 26, 2025

Profile

Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.
IPO date
Jun 18, 2021
Employees
133
Domiciled in
DE
Incorporated in
NL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑12
Income
Revenues
314
34.76%
233
-98.86%
20,376
 
Cost of revenue
125,785
144,831
140,748
Unusual Expense (Income)
NOPBT
(125,471)
(144,598)
(120,372)
NOPBT Margin
Operating Taxes
1,016
6,229
(3,989)
Tax Rate
NOPAT
(126,487)
(150,827)
(116,383)
Net income
(40,224)
-71.56%
(141,411)
6.64%
(132,612)
29.86%
Dividends
Dividend yield
Proceeds from repurchase of equity
225
4,636
409,884
BB yield
-0.10%
-1.12%
-33.43%
Debt
Debt current
550
180
Long-term debt
20,132
15,341
743
Deferred revenue
Other long-term liabilities
10,175
265,401
383,437
Net debt
(250,238)
(264,343)
(389,282)
Cash flow
Cash from operating activities
(84,118)
(104,467)
(63,246)
CAPEX
(590)
(1,024)
(1,128)
Cash from investing activities
(53,295)
(86,848)
(81,276)
Cash from financing activities
(8,355)
20,785
409,862
FCF
(127,763)
(151,606)
(116,461)
Balance
Cash
179,257
273,109
362,266
Long term investments
91,663
6,755
27,759
Excess cash
270,904
279,852
389,006
Stockholders' equity
(550,471)
(508,302)
(339,086)
Invested Capital
823,939
791,802
724,180
ROIC
ROCE
EV
Common stock shares outstanding
158,834
155,720
160,677
Price
1.41
-46.99%
2.66
-65.14%
7.63
 
Market cap
223,956
-45.93%
414,214
-66.21%
1,225,966
 
EV
(24,928)
154,897
845,735
EBITDA
(125,152)
(144,430)
(120,325)
EV/EBITDA
0.20
Interest
2,656
1,915
Interest/NOPBT